Zensar delivered a resilient Q3FY26 performance in a challenging demand environment, with revenue of USD 160.5mn, growing 1.3%YoY in CC term, supported by healthy offshore volume growth. While topline growth remains modest due to continued weakness in the TMT vertical and some pressure in healthcare, the company's execution on profitability was strong. EBITDA margin expanded sharply by 200 basis points sequentially to 17.4%, driven by better offshore mix, higher utilization, forex benefits, and tight cost control. The order book improved to ~USD 180mn with a book-to-bill of 1.12x, providing...